Cargando…
Early Results of Mechanochemical Ablation with Flebogrif® in great Saphenous Vein Insufficiency: does Polidocanol Concentration Affect Outcome?
BACKGROUND: Flebogrif® (Balton, Poland) is a novel mechanochemical ablation (MOCA) device for saphenous vein insufficiency. It combines endothelial damage performed by radial retractable cutting hooks together with chemical ablation through sclerosant injection of 3% polidocanol foam according to it...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università di Salerno
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039266/ https://www.ncbi.nlm.nih.gov/pubmed/32123682 |
_version_ | 1783500791099686912 |
---|---|
author | Ammollo, RP Petrone, A Giribono, AM Ferrante, L del Guercio, L Bracale, UM |
author_facet | Ammollo, RP Petrone, A Giribono, AM Ferrante, L del Guercio, L Bracale, UM |
author_sort | Ammollo, RP |
collection | PubMed |
description | BACKGROUND: Flebogrif® (Balton, Poland) is a novel mechanochemical ablation (MOCA) device for saphenous vein insufficiency. It combines endothelial damage performed by radial retractable cutting hooks together with chemical ablation through sclerosant injection of 3% polidocanol foam according to its IFU. The objective of this study is to evaluate Flebogrif’s efficacy in terms of recanalization rate and recurrence by varying polidocanol foam concentrations. METHODS: We performed 24 MOCAs on 23 patients with Flebogrif® between January and May 2019. In 12 cases the polidocanol foam was prepared at a 3% concentration, and in another 12 at 1.5%. Great saphenous vein (GSV) recanalization and truncular recurrence were evaluated at 1 and 3 months with a Duplex Ultrasound Anatomy (DUS) examination. RESULTS: At 1- and 3-month follow-ups, none of the 14 patients treated with the polidocanol 3% foam were observed to have had great saphenous vein GSV recanalization and truncular recurrence. Only 2 of the 14 (14.3%) cases treated with polidocanol 1.5% foam showed evidence of recanalization within the first centimetres from the sapheno-femoral junction (p > .05). All patients experienced clinical benefits without recurrence of symptoms. CONCLUSION: MOCA with Flebogrif® is a safe, relatively inexpensive and effective alternative to standard methods in the treatment of saphenous insufficiency with encouraging short-term results. Despite our relatively small patient sample, no statistical significance in evidence of recurrence in the group of patients treated with 3% foam and those treated with 1.5% foam was noted. Longer term analysis of GSV patency and recurrence is necessary to further evaluate Flebogrif’s impact and actual indications in the treatment of chronic venous disease. |
format | Online Article Text |
id | pubmed-7039266 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Università di Salerno |
record_format | MEDLINE/PubMed |
spelling | pubmed-70392662020-03-02 Early Results of Mechanochemical Ablation with Flebogrif® in great Saphenous Vein Insufficiency: does Polidocanol Concentration Affect Outcome? Ammollo, RP Petrone, A Giribono, AM Ferrante, L del Guercio, L Bracale, UM Transl Med UniSa Articles BACKGROUND: Flebogrif® (Balton, Poland) is a novel mechanochemical ablation (MOCA) device for saphenous vein insufficiency. It combines endothelial damage performed by radial retractable cutting hooks together with chemical ablation through sclerosant injection of 3% polidocanol foam according to its IFU. The objective of this study is to evaluate Flebogrif’s efficacy in terms of recanalization rate and recurrence by varying polidocanol foam concentrations. METHODS: We performed 24 MOCAs on 23 patients with Flebogrif® between January and May 2019. In 12 cases the polidocanol foam was prepared at a 3% concentration, and in another 12 at 1.5%. Great saphenous vein (GSV) recanalization and truncular recurrence were evaluated at 1 and 3 months with a Duplex Ultrasound Anatomy (DUS) examination. RESULTS: At 1- and 3-month follow-ups, none of the 14 patients treated with the polidocanol 3% foam were observed to have had great saphenous vein GSV recanalization and truncular recurrence. Only 2 of the 14 (14.3%) cases treated with polidocanol 1.5% foam showed evidence of recanalization within the first centimetres from the sapheno-femoral junction (p > .05). All patients experienced clinical benefits without recurrence of symptoms. CONCLUSION: MOCA with Flebogrif® is a safe, relatively inexpensive and effective alternative to standard methods in the treatment of saphenous insufficiency with encouraging short-term results. Despite our relatively small patient sample, no statistical significance in evidence of recurrence in the group of patients treated with 3% foam and those treated with 1.5% foam was noted. Longer term analysis of GSV patency and recurrence is necessary to further evaluate Flebogrif’s impact and actual indications in the treatment of chronic venous disease. Università di Salerno 2020-02-20 /pmc/articles/PMC7039266/ /pubmed/32123682 Text en http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Articles Ammollo, RP Petrone, A Giribono, AM Ferrante, L del Guercio, L Bracale, UM Early Results of Mechanochemical Ablation with Flebogrif® in great Saphenous Vein Insufficiency: does Polidocanol Concentration Affect Outcome? |
title | Early Results of Mechanochemical Ablation with Flebogrif® in great Saphenous Vein Insufficiency: does Polidocanol Concentration Affect Outcome? |
title_full | Early Results of Mechanochemical Ablation with Flebogrif® in great Saphenous Vein Insufficiency: does Polidocanol Concentration Affect Outcome? |
title_fullStr | Early Results of Mechanochemical Ablation with Flebogrif® in great Saphenous Vein Insufficiency: does Polidocanol Concentration Affect Outcome? |
title_full_unstemmed | Early Results of Mechanochemical Ablation with Flebogrif® in great Saphenous Vein Insufficiency: does Polidocanol Concentration Affect Outcome? |
title_short | Early Results of Mechanochemical Ablation with Flebogrif® in great Saphenous Vein Insufficiency: does Polidocanol Concentration Affect Outcome? |
title_sort | early results of mechanochemical ablation with flebogrif® in great saphenous vein insufficiency: does polidocanol concentration affect outcome? |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039266/ https://www.ncbi.nlm.nih.gov/pubmed/32123682 |
work_keys_str_mv | AT ammollorp earlyresultsofmechanochemicalablationwithflebogrifingreatsaphenousveininsufficiencydoespolidocanolconcentrationaffectoutcome AT petronea earlyresultsofmechanochemicalablationwithflebogrifingreatsaphenousveininsufficiencydoespolidocanolconcentrationaffectoutcome AT giribonoam earlyresultsofmechanochemicalablationwithflebogrifingreatsaphenousveininsufficiencydoespolidocanolconcentrationaffectoutcome AT ferrantel earlyresultsofmechanochemicalablationwithflebogrifingreatsaphenousveininsufficiencydoespolidocanolconcentrationaffectoutcome AT delguerciol earlyresultsofmechanochemicalablationwithflebogrifingreatsaphenousveininsufficiencydoespolidocanolconcentrationaffectoutcome AT bracaleum earlyresultsofmechanochemicalablationwithflebogrifingreatsaphenousveininsufficiencydoespolidocanolconcentrationaffectoutcome |